Pallante Benedetta A, Edelberg Jay M
Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.
Am Heart Hosp J. 2006 Spring;4(2):95-7. doi: 10.1111/j.1541-9215.2006.04651.x.
Realizing the promise of therapeutic cardiac regeneration requires the targeting of accessible cell sources to promote neomyogenesis for the injured heart. After initial trials with cardiac myocytes and skeletal muscle progenitor cells (myoblasts), the rapid advances of stem cell technology have established the feasibility of endogenous stem cells to serve as donor cells for cellular cardiomyoplasty. In particular, bone marrow-derived stem cells have a great potential for clinical application due to their extracardiac locale and capacity to give rise to functional cardiac myocytes. The recent identification of resident cardiac stem cells also offers the opportunity to regenerate the infarcted myocardium, using the cells from the heart for ex vivo expansion or as targets for in vivo induction. To this end, future advances in cellular cardiomyoplasty may likely be based on therapies stimulating the trophic/cellular interactions that direct exogenous/endogenous stem cell-mediated cardiac regeneration.
要实现治疗性心脏再生的前景，需要靶向可及的细胞来源，以促进受损心脏的新肌生成。在用心肌细胞和骨骼肌祖细胞（成肌细胞）进行初步试验后，干细胞技术的迅速发展已证实内源性干细胞作为细胞心肌成形术供体细胞的可行性。特别是，骨髓来源的干细胞因其心外定位和产生功能性心肌细胞的能力而具有巨大的临床应用潜力。最近对心脏驻留干细胞的鉴定也为梗死心肌的再生提供了机会，可利用心脏中的细胞进行体外扩增或作为体内诱导的靶点。为此，细胞心肌成形术未来的进展可能基于刺激营养/细胞相互作用的疗法，这些相互作用指导外源性/内源性干细胞介导的心脏再生。
